Literature DB >> 17671965

Polymorphisms TaqI A of the DRD2, BalI of the DRD3, exon III repeat of the DRD4, and 3' UTR VNTR of the DAT: association with childhood ADHD in male African-Caribbean cocaine dependents?

Nicolas Ballon1, Sophie Leroy, Christianne Roy, Marie-Chantal Bourdel, Jean-Pierre Olie, Aimé Charles-Nicolas, Marie-Odile Krebs, Marie-France Poirier.   

Abstract

The conflicting results reported by genetic studies with the variants of the genes coding for the dopaminergic system in cocaine addicts could be partially explained by the difficulties to constitute homogenous sample of patients. Childhood attention-deficit/hyperactivity disorder (ADHD), and/or impulsivity are frequently associated with cocaine addiction and could participate in the heterogeneity of the samples in cocaine addicts. Accordingly, it is hypothesized that cocaine addiction would be associated with the variants of the genes coding for the dopamine system in an homogenized sample of cocaine addicts, especially in individuals with childhood ADHD comorbidity, or with a high impulsivity score. The potential association of the variants TaqI A of the DRD2, BalI of the DRD3, exon III repeat of the DRD4, and 3' UTR VNTR of the DAT was examined in African-Caribbean males, smoked-cocaine dependents. All the subjects were assessed with the Diagnostic Interview of Genetic Studies, the Barratt's impulsivity scale, and the Wender Utah rating scale for childhood ADHD. A positive association was found with the DRD2 and DRD4 polymorphisms in the subgroups of patients with childhood ADHD, or with a high impulsivity score, which represented, respectively, 53.3 and 73.0% of the patients. Conversely, no positive association was found for any of the polymorphisms studied when the group of patients was examined as a whole. Therefore, our results suggest that the clinical dimensions of childhood ADHD and of impulsivity could be taken into account to homogenize the samples of patients in cocaine association studies. 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17671965     DOI: 10.1002/ajmg.b.30540

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  13 in total

1.  Association analysis between polymorphisms in the conserved dopamine neurotrophic factor (CDNF) gene and cocaine dependence.

Authors:  Falk W Lohoff; Paul J Bloch; Thomas N Ferraro; Wade H Berrettini; Helen M Pettinati; Charles A Dackis; Charles P O'Brien; Kyle M Kampman; David W Oslin
Journal:  Neurosci Lett       Date:  2009-02-21       Impact factor: 3.046

Review 2.  Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.

Authors:  Carolina Céspedes-Garro; María-Eugenia G Naranjo; Fernanda Rodrigues-Soares; Adrián LLerena; Jorge Duconge; Lazara K Montané-Jaime; Hilda Roblejo; Humberto Fariñas; María de Los A Campos; Ronald Ramírez; Víctor Serrano; Carmen I Villagrán; Eva M Peñas-LLedó
Journal:  Pharmacogenomics       Date:  2016-09-16       Impact factor: 2.533

Review 3.  Low dopamine function in attention deficit/hyperactivity disorder: should genotyping signify early diagnosis in children?

Authors:  Mark S Gold; Kenneth Blum; Marlene Oscar-Berman; Eric R Braverman
Journal:  Postgrad Med       Date:  2014-01       Impact factor: 3.840

4.  Neuronal calcium sensor-1 and cocaine addiction: a genetic association study in African-Americans and European Americans.

Authors:  Pushpinder K Multani; Toni-Kim Clarke; Sneha Narasimhan; Lisa Ambrose-Lanci; Kyle M Kampman; Helen M Pettinati; David W Oslin; Charles P O'Brien; Wade H Berrettini; Falk W Lohoff
Journal:  Neurosci Lett       Date:  2012-09-20       Impact factor: 3.046

Review 5.  Molecular genetics of attention-deficit/hyperactivity disorder: an overview.

Authors:  Tobias Banaschewski; Katja Becker; Susann Scherag; Barbara Franke; David Coghill
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-02-10       Impact factor: 4.785

Review 6.  Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).

Authors:  Kenneth Blum; Thomas J H Chen; B William Downs; Abdalla Bowirrat; Roger L Waite; Eric R Braverman; Margaret Madigan; Marlene Oscar-Berman; Nicholas DiNubile; Eric Stice; John Giordano; Siobhan Morse; Mark Gold
Journal:  Postgrad Med       Date:  2009-11       Impact factor: 3.840

7.  Genetic variants in the cocaine- and amphetamine-regulated transcript gene (CARTPT) and cocaine dependence.

Authors:  Falk W Lohoff; Paul J Bloch; Andrew E Weller; Aleksandra H Nall; Glenn A Doyle; Russell J Buono; Thomas N Ferraro; Kyle M Kampman; Helen M Pettinati; Charles A Dackis; David W Oslin; Charles P O'Brien; Wade H Berrettini
Journal:  Neurosci Lett       Date:  2008-05-24       Impact factor: 3.046

Review 8.  The DRD4 exon 3 VNTR polymorphism and addiction-related phenotypes: a review.

Authors:  John McGeary
Journal:  Pharmacol Biochem Behav       Date:  2009-03-29       Impact factor: 3.533

9.  Genotype and ancestry modulate brain's DAT availability in healthy humans.

Authors:  Elena Shumay; John Chen; Joanna S Fowler; Nora D Volkow
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

10.  Repeat variation in the human PER2 gene as a new genetic marker associated with cocaine addiction and brain dopamine D2 receptor availability.

Authors:  E Shumay; J S Fowler; G-J Wang; J Logan; N Alia-Klein; R Z Goldstein; T Maloney; C Wong; N D Volkow
Journal:  Transl Psychiatry       Date:  2012-03-06       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.